MTOR and neoplasm: In conclusion, the interaction between SIN1 and active RAS places SIN1 at the crossroads between the PI3K‐AKT‐mTOR pathway and the MAPK pathway, particularly in cells with oncogenic mutations of RAS which are present in about 30% of human tumours.